GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Advagene Biopharma Co Ltd (ROCO:6709) » Definitions » Capex-to-Operating-Income

Advagene Biopharma Co (ROCO:6709) Capex-to-Operating-Income : 0.00 (As of Jun. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Advagene Biopharma Co Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Advagene Biopharma Co's Capital Expenditure for the six months ended in Jun. 2023 was NT$0.00 Mil. Its Operating Income for the six months ended in Jun. 2023 was NT$-47.40 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


Advagene Biopharma Co Capex-to-Operating-Income Historical Data

The historical data trend for Advagene Biopharma Co's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Advagene Biopharma Co Capex-to-Operating-Income Chart

Advagene Biopharma Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Income
Get a 7-Day Free Trial - - - - -

Advagene Biopharma Co Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Advagene Biopharma Co's Capex-to-Operating-Income

For the Biotechnology subindustry, Advagene Biopharma Co's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Advagene Biopharma Co's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Advagene Biopharma Co's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Advagene Biopharma Co's Capex-to-Operating-Income falls into.



Advagene Biopharma Co Capex-to-Operating-Income Calculation

Advagene Biopharma Co's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (0) / -93.336
=N/A

Advagene Biopharma Co's Capex-to-Operating-Income for the quarter that ended in Jun. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (0) / -47.398
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Advagene Biopharma Co  (ROCO:6709) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Advagene Biopharma Co Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Advagene Biopharma Co's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Advagene Biopharma Co (ROCO:6709) Business Description

Traded in Other Exchanges
N/A
Address
Sector 1, Neihu Road, 6 Floor, No.308, Neihu District, Taipei, TWN, 114
Advagene Biopharma Co Ltd is a Taiwan based immune-modulatory platform-based drug developer. The company has completed technology transfer with DCB for detoxified LT Adjuvant Technology Platform. Its product development includes nasal spray influenza vaccine (LT-Flu), allergy vaccines (LT-Allergy), and other vaccines.

Advagene Biopharma Co (ROCO:6709) Headlines

No Headlines